ARTICLE SUMMARY:
Many venture capitalists have fled medtech in search of higher, faster returns from biopharma. Now may be just the time for investors to return to attractively-valued medical device assets.
“I love medtech, but it’s a tough space to make good returns.” Those are the words of one European venture capitalist, whose firm has quietly exited medtech in favor of biopharma.
